COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.
Saved in:
Main Authors: | V. A. Sulimov (Author), D. A. Napalkov (Author), A. A. Sokolova (Author) |
---|---|
Format: | Book |
Published: |
Столичная издательская компания,
2015-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
by: V. A. Sulimov, et al.
Published: (2015) -
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015) -
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015) -
Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy
by: D. A. Napalkov, et al.
Published: (2019) -
Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
by: M. A. Gabitova, et al.
Published: (2020)